( BOSTON -- Surface Logix Inc. today ann...)Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease,Health

BOSTON, -- Surface Logix Inc. today announced the initiation of a Phase 2a clinical trial for SLx-2101 in patients with secondary Raynaud's disease. SLx-2101 is a novel , long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's, a vasospastic disorder of small blood vessels leading to a marked reduction of blood flow to areas such as the fingers and toes. Often triggered by exposure to cold, Raynaud's is associated with painful blue or white digits, and in severe cases, may lead to the development of digital ulcers.

"PDE-5 inhibition holds promise in several cardiovascular indications, though many disorders such as Raynaud's are currently not addressed by marketed PDE-5 inhibitors," commented Paul Sweetnam, Ph.D., Chief Scientific Officer of Surface Logix. "We used our novel chemistry platform to design SLx-2101 to have a profile that would deliver fast onset and long duration of therapeutic effects in difficult-to-treat conditions such as Raynaud's, potentially enabling quicker, longer-lasting relief to patients."

"The initiation of this trial is part of Surface Logix's multiple indication development plan for SLx-2101. We believe that it has applicability in cardiovascular indications beyond erectile dysfunction and are therefore pursuing its advancement in specialized indications, such as Raynaud's, as well as in larger cardiovascular markets," said Jim Mahoney, President and Chief Executive Officer of Surface Logix.

The Phase 2a trial is a single European center, randomized, double-blind, placebo-controlled, crossover pilot study that will enroll 20 patients with secondary Raynaud's disease. The trial is designed to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days. The primary objective of this trial is to investigate the severity of secondary Raynaud's disease-related attacks
'"/>




Page: 1 2
Related medicine news :

1. Lunar Forces Affect The Surface Of The Earth
2. Controversy Over The Fee Structure In Private Medical Colleges Surfaces Yet Again
3. Meningitis C Surfaces in Toronto:Public Alerted
4. New Study Links Western Wildfires to Atlantic Ocean Surface Temperatures
5. Copper Alloys Surfaces Touted As Pathogen Killers
6. Flesh-eating Bugs Surface in Singapore
7. InfoLogix, Inc. the Leading Healthcare Technology Company SaysHealthcare Informatics
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. Natco Pharma Commences Production At Dehradun Unit
10. Chinas First Gay Health Clinic Commences Operations
11. Mental Health - NHS Trust Commences Specialist Transition Service